FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979581457> ?p ?o ?g. }

• W2979581457 abstract "Abstract Abstract 4957 Background Over 40% of patients with the most common lymphoid malignancy worldwide, DLBL, are over the age of 70. Although R-CHOP is inarguably the mainstay of therapy for DLBL patients, a significant number of elderly patients do not tolerate the regimen due to underlying frailty and/or co-morbidities. Most elderly patients with significant co-morbidities have limited treatment options and are not offered anthracycline-containing chemotherapy due to concerns regarding toxicity. Here we describe our single center experience with CEEP, a lower intensity regimen for elderly patients with newly diagnosed or relapsed DLBL whom are deemed inappropriate for CHOP-based chemotherapy. Method All patients >70 years old (median 78.5, range 71 – 85) with histologically proven DLBL treated with CEEP ± Rituximab (R) at Royal Prince Alfred Hospital from 2000 to 2010 were retrospectively reviewed. Modified CEEP, Cyclophosphamide 300mg/m2 Day 1 (D1) and D15, Epirubicin 50mg/m2 D1 and D15, Etoposide 100mg/m2 D1 and D15, and Prednisolone 50mg D1-D5 (reduced dose from original CEEP protocol) was administered every 2 weeks. Rituximab 375mg/m2 (when approved for use in Australia) was administered every 28 days. As per institutional protocol, all patients received Bactrim prophylaxis for Pneumocystis. Baseline characteristics, Charlson Comorbidity Index, Revised International Prognostic Index (RIPI), the number of CEEP cycles, treatment response and toxicity from treatment were identified and reviewed. Results A total of 22 patients were identified, 10 were male. 15 received CEEP as initial therapy, and 7 for relapsed disease. 23% (n=5) had an ECOG score ≥ 2. 55% (n=12) had RIPI ≥ 3. All patients had a Charlson Comorbidity Index ≥ 2, with 23% (n=5) ≥ 5, which was considered sufficient to preclude conventional CHOP-based chemotherapy. Median cardiac ejection fraction was 62% (range 55 – 85%). 73% (n=16) received Rituximab and 50% (n=11) received primary GCSF prophylaxis. The median number of CEEP ± R cycles was 6 (range 2 – 9 cycles). 5% (n=1) required dose reduction and 9% (n=2) required delays in treatment due to haematological toxicity. Median follow-up was 10.0 months (range 1 – 92.7 months). At completion of therapy, complete responses (CR) were demonstrated in 10 patients (45%), with partial responses (PR) seen in 32% (n=7). 18% (n=4) demonstrated progressive disease (PD) despite therapy. Of the 7 patients with relapsed disease prior to CEEP ± R, CR was seen in 2 cases, both of whom had previous exposure to R-CVP (cyclophosphamide, vincristine, prednisolone) chemotherapy. At most recent follow up, 32% (n=7) have remained in CR with a median follow up period of 28.1 months (range 13 – 92.7 months), 36% (n=8) had disease progression, 9% (n=2) demonstrated stable residual disease, while 23% (n=5) have died. Of the 5 deaths, 3 were attributed to progressive DLBL. The other deaths were a result of complications following further salvage chemotherapy. Grade 3 – 4 haematological toxicity was observed in 72% (n=16) of patients. Febrile neutropenia occurred in 41% (n=9). Overall, 50% (n=11) required at least one re-admission to hospital. Non-haematological grade 3 – 4 toxicity was detected in 2 patients, one of whom suffered unstable angina in the setting of anaemia, the other an acute cerebrovascular event in the setting of new atrial flutter post-chemotherapy. Discussion Although limited by a small sample size, our retrospective single center experience demonstrates that CEEP ± R chemotherapy can be administered to elderly patients with significant co-morbidities. Our cohort was all aged >70, with medical co-morbidities leading to the unsuitability of conventional CHOP-based therapy. Whilst an overall response rate of 77% (CR + PR) was observed, on prolonged follow up, 32% of patients remained in CR. Significant haematological toxicity (72%) and infectious complications (41%) were observed, however no deaths were directly attributed to the chemotherapy. Future prospective studies are required to further evaluate the safety and efficacy of R-CEEP in the elderly. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979581457 created "2019-10-18" @default.
• W2979581457 creator A5006163842 @default.
• W2979581457 creator A5014318165 @default.
• W2979581457 creator A5015360282 @default.
• W2979581457 creator A5021860262 @default.
• W2979581457 creator A5042597609 @default.
• W2979581457 creator A5047415265 @default.
• W2979581457 creator A5057006053 @default.
• W2979581457 creator A5080617550 @default.
• W2979581457 creator A5087490834 @default.
• W2979581457 date "2011-11-18" @default.
• W2979581457 modified "2023-09-27" @default.
• W2979581457 title "Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience" @default.
• W2979581457 doi "https://doi.org/10.1182/blood.v118.21.4957.4957" @default.
• W2979581457 hasPublicationYear "2011" @default.
• W2979581457 type Work @default.
• W2979581457 sameAs 2979581457 @default.
• W2979581457 citedByCount "0" @default.
• W2979581457 crossrefType "journal-article" @default.
• W2979581457 hasAuthorship W2979581457A5006163842 @default.
• W2979581457 hasAuthorship W2979581457A5014318165 @default.
• W2979581457 hasAuthorship W2979581457A5015360282 @default.
• W2979581457 hasAuthorship W2979581457A5021860262 @default.
• W2979581457 hasAuthorship W2979581457A5042597609 @default.
• W2979581457 hasAuthorship W2979581457A5047415265 @default.
• W2979581457 hasAuthorship W2979581457A5057006053 @default.
• W2979581457 hasAuthorship W2979581457A5080617550 @default.
• W2979581457 hasAuthorship W2979581457A5087490834 @default.
• W2979581457 hasConcept C126322002 @default.
• W2979581457 hasConcept C141071460 @default.
• W2979581457 hasConcept C2776694085 @default.
• W2979581457 hasConcept C2776715498 @default.
• W2979581457 hasConcept C2776755627 @default.
• W2979581457 hasConcept C2776907518 @default.
• W2979581457 hasConcept C2777063308 @default.
• W2979581457 hasConcept C2778119113 @default.
• W2979581457 hasConcept C2778336483 @default.
• W2979581457 hasConcept C2778476033 @default.
• W2979581457 hasConcept C2778559949 @default.
• W2979581457 hasConcept C2778850193 @default.
• W2979581457 hasConcept C2779338263 @default.
• W2979581457 hasConcept C2780653079 @default.
• W2979581457 hasConcept C2780835546 @default.
• W2979581457 hasConcept C2781413609 @default.
• W2979581457 hasConcept C71924100 @default.
• W2979581457 hasConcept C90924648 @default.
• W2979581457 hasConceptScore W2979581457C126322002 @default.
• W2979581457 hasConceptScore W2979581457C141071460 @default.
• W2979581457 hasConceptScore W2979581457C2776694085 @default.
• W2979581457 hasConceptScore W2979581457C2776715498 @default.
• W2979581457 hasConceptScore W2979581457C2776755627 @default.
• W2979581457 hasConceptScore W2979581457C2776907518 @default.
• W2979581457 hasConceptScore W2979581457C2777063308 @default.
• W2979581457 hasConceptScore W2979581457C2778119113 @default.
• W2979581457 hasConceptScore W2979581457C2778336483 @default.
• W2979581457 hasConceptScore W2979581457C2778476033 @default.
• W2979581457 hasConceptScore W2979581457C2778559949 @default.
• W2979581457 hasConceptScore W2979581457C2778850193 @default.
• W2979581457 hasConceptScore W2979581457C2779338263 @default.
• W2979581457 hasConceptScore W2979581457C2780653079 @default.
• W2979581457 hasConceptScore W2979581457C2780835546 @default.
• W2979581457 hasConceptScore W2979581457C2781413609 @default.
• W2979581457 hasConceptScore W2979581457C71924100 @default.
• W2979581457 hasConceptScore W2979581457C90924648 @default.
• W2979581457 hasLocation W29795814571 @default.
• W2979581457 hasOpenAccess W2979581457 @default.
• W2979581457 hasPrimaryLocation W29795814571 @default.
• W2979581457 hasRelatedWork W2095394060 @default.
• W2979581457 hasRelatedWork W2115761690 @default.
• W2979581457 hasRelatedWork W2243879287 @default.
• W2979581457 hasRelatedWork W2322762869 @default.
• W2979581457 hasRelatedWork W2386817084 @default.
• W2979581457 hasRelatedWork W2550172655 @default.
• W2979581457 hasRelatedWork W2550234544 @default.
• W2979581457 hasRelatedWork W2551451258 @default.
• W2979581457 hasRelatedWork W2557062468 @default.
• W2979581457 hasRelatedWork W2560256985 @default.
• W2979581457 hasRelatedWork W2563316179 @default.
• W2979581457 hasRelatedWork W2578159471 @default.
• W2979581457 hasRelatedWork W2586617225 @default.
• W2979581457 hasRelatedWork W2591810753 @default.
• W2979581457 hasRelatedWork W2594693420 @default.
• W2979581457 hasRelatedWork W2901183349 @default.
• W2979581457 hasRelatedWork W2977712125 @default.
• W2979581457 hasRelatedWork W2983619629 @default.
• W2979581457 hasRelatedWork W3163797190 @default.
• W2979581457 hasRelatedWork W3165372441 @default.
• W2979581457 isParatext "false" @default.
• W2979581457 isRetracted "false" @default.
• W2979581457 magId "2979581457" @default.
• W2979581457 workType "article" @default.